Financial Performance - The company's operating revenue for the first half of 2024 was ¥70,947,999.30, a decrease of 44.01% compared to ¥126,708,771.81 in the same period last year[16]. - The net profit attributable to shareholders was ¥23,449,034.92, down 56.55% from ¥53,965,557.28 year-on-year[16]. - The gross profit margin for the first half of 2024 was 44.19%, down from 55.25% in the same period last year[16]. - The basic earnings per share decreased by 65.56% to ¥0.31 from ¥0.90 year-on-year[16]. - The net cash flow from operating activities was 18,507,184.68 yuan, reflecting a decline of 51.91% compared to the previous year[29]. - The total operating income for the period was ¥26,968,545.47, down 57.0% from ¥62,835,042.09 in the previous period[199]. - The company reported a net profit of ¥23,449,034.92, a decrease of 56.5% compared to ¥53,965,557.28 from the previous year[200]. Assets and Liabilities - The total assets increased by 115.57% to ¥662,601,544.39 from ¥307,375,267.23 at the end of the previous year[17]. - The total liabilities rose by 64.15% to ¥37,724,623.61 compared to ¥22,982,422.60 at the end of the previous year[17]. - The net asset attributable to shareholders increased by 119.72% to ¥624,876,920.78 from ¥284,392,844.63 year-on-year[17]. - Cash and cash equivalents increased by 210.46% to ¥314,755,697.46, primarily due to funds raised from a public stock offering[34]. - The total assets and liabilities combined reached ¥662,601,544.39, up from ¥307,375,267.23, marking a growth of 115.5%[99]. Shareholder and Dividend Information - The company completed a cash distribution of ¥5.00 per share to shareholders based on a total of 80,000,000 shares on June 11, 2024[3]. - The company plans to distribute a cash dividend of ¥5.00 per share based on the current share capital of 80,000,000 shares[196]. - The actual controllers committed to extend the lock-up period of their shares by 12 months until August 2, 2026[61]. - The actual controllers promised to enhance the cash dividend policy to improve investor returns[61]. Market and Competitive Position - The global veterinary drug market size was approximately $44.59 billion in 2022, expected to reach $83.76 billion by 2030, with a CAGR of 8.2%[31]. - The domestic veterinary drug market is projected to grow from 68.62 billion yuan in 2021 to 139.57 billion yuan by 2027, with a CAGR of 12.56%[32]. - The company has strengthened its domestic and international product registrations to lay the foundation for future revenue growth[29]. - The company is currently benefiting from tax incentives related to high-tech enterprises, which could be impacted if conditions change[52]. Research and Development - The company established a new R&D building in May 2024 to enhance its research capabilities[2]. - The company is increasing R&D investment to mitigate risks from market competition and product concentration, focusing on developing new products and optimizing existing processes[52]. - Research and development expenses for the first half of 2024 were CNY 4,047,841.27, a decrease of 18.3% compared to CNY 4,953,819.84 in the first half of 2023[100]. Environmental and Safety Compliance - The company adheres to the "three-level standard" for wastewater discharge, ensuring compliance with environmental regulations[43]. - The company’s waste gas emissions are treated according to national standards, with measures in place for VOCs control and acid-base treatment[47]. - The company has implemented a waste management strategy focusing on resource recovery, reduction, and harmlessness, with hazardous waste being disposed of by qualified third-party institutions[48]. - The company is committed to improving safety and environmental management to prevent potential accidents[53]. Governance and Management - The board of directors consists of 6 members, while the supervisory board has 3 members, indicating a stable governance structure[91]. - The company has appointed new management personnel, including Mr. Shu Lin and Mr. Yang Chun, enhancing its leadership team[95]. - There were changes in independent directors, with Li Liangchen resigning for personal reasons and Shu Lin being appointed as a new independent director[94]. Related Party Transactions - The company has a debt relationship with related parties, with accounts payable to Ye Shan Hai and Ye Jin Zhi amounting to CNY 9,798,100.00 and CNY 9,900,000.00 respectively[59]. - The company will ensure that any related party transactions are conducted on an equal and voluntary basis, adhering to fair and reasonable pricing principles[75]. Stock Price Stabilization Measures - The company has committed to stabilizing its stock price for three years following its public offering on the Beijing Stock Exchange, with specific measures to be implemented if stock prices fall below the issuance price for 10 consecutive trading days within the first month[66]. - The company’s stock price stabilization plan is designed to ensure compliance with the listing conditions of the Beijing Stock Exchange[67]. - The company will not allow any share transfers by directors and senior management during a lock-up period of 12 months post-IPO, with a maximum of 25% of their holdings allowed for transfer annually thereafter[65]. Financial Reporting and Compliance - The financial statements are prepared based on the going concern assumption, indicating no significant doubts about the company's ability to continue operations for the next 12 months[115]. - The company adheres to the accounting standards set by the Ministry of Finance and reflects its financial status accurately as of June 30, 2024[116]. - The company guarantees that the prospectus and other issuance documents do not contain false records or misleading statements, and assumes legal responsibility for their authenticity, accuracy, and completeness[71].

Investment Rating - The report does not explicitly provide an investment rating for the company Core Insights - The actual controller of the company, Ye Shan Hai, and his daughter plan to buy a maximum of 100 shares, amounting to 1990 yuan, which has been described as "the stingiest buyback in securities history" [1][2] - The company has faced criticism for its high gross profit margins, which are significantly above industry averages, raising questions about the sustainability and rationale behind these figures [12][21] - The company has been involved in related party transactions, particularly with Juhua Group, which is a major supplier, and this raises concerns about potential conflicts of interest [30][31] Summary by Sections Company Overview - The company primarily operates in the raw material pharmaceutical sector, focusing on sulfonamide raw materials and intermediates [5][6] - The company reported a revenue of 2.1 billion yuan in 2023, with 1.31 billion yuan coming from veterinary raw materials, accounting for 62% of total revenue [8] Financial Performance - In the first half of 2023, the company reported a total revenue of 2.1 billion yuan, with a gross profit margin of 52.67% [38] - The gross profit margin for veterinary raw materials was reported at 53.39%, while the margin for intermediates was 55.49% [18][20] - The company experienced a decline in revenue and net profit in 2023, with a year-on-year decrease of 18.65% in revenue and a 24.78% drop in net profit [38] Gross Margin Analysis - The company's gross margin has been unusually high, with historical margins showing a significant increase from 21.6% in 2018 to over 50% in recent years [12][14] - The report indicates that the company's gross margin is the highest in its industry, raising questions about the validity of these figures compared to competitors [14][21] Related Party Transactions - The company has significant transactions with Juhua Group, which is both a major supplier and has connections to the company's actual controller, raising potential conflict of interest concerns [30][31] - The company has also engaged in transactions with other suppliers that have connections to the actual controller, which could indicate a lack of independence in its procurement processes [32][34] Management and Governance - The company has faced scrutiny for its management practices, including the use of idle funds for bank financial products without proper disclosure, leading to regulatory warnings [40][41] - The company has committed to improving its governance and compliance practices in response to regulatory feedback [41]

一、 授权委托理财情况 （一）已授权委托理财基本信息 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲置募集资金进行现金管理的公告》（公告编号：2024-069）。 （二）本次委托理财披露的标准 根据《北京证券交易所股票上市规则（试行）》中相关规定，交易的成交金 额占上市公司最近一期经审计净资产的 10%以上且超过 1,000.00 万元的应当予 以披露；上市公司连续 12 个月滚动发生理财的，以该期间最高余额为成交额， 适用上述标准。 截至目前 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 公司于 2024 年 5 月 16 日召开第三届董事会第十六次会议、第三届监事会 第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通 过了《关于使用闲置自有资金进行现金管理的议案》，基于公司经营稳定，财务 状况稳健，有较充裕的资金及有效的风险控制制度，在确保公司正常经营活动 资金需求的前提下，公司拟使用部分闲置自有资金进行管理，以提高资金使用 效率和收益，为公司股东谋取更好的回报。公司拟进行的现金管理的金额不超 过人民币 1 亿元（含本数），资金来源为公司闲置自有资金。在上述额度内，资 金可以循环滚动使用，委托理财取得的收益可进行再投资，再投资的金额不包 含在上述额度以内。具体内容详见公司在北京证券交易所信息披露平台 （www.bse.cn）披露的《关于使用闲置自有资金进行现金管理的公告》（公告编 号：2024-070）。 （二）本次委托理财披露的标准 根据《北京 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-080 浙江海昇药业股份有限公司 关于使用部分闲置募集资金及闲置自有资金购买理财产品的 进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲置募集资金进行现金管理的公告》 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-078 （二）本次委托理财披露的标准 浙江海昇药业股份有限公司 关于使用部分闲置募集资金及闲置自有资金购买理财产品的 进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲 ...

法律意见书 浙江天册律师事务所 关于 浙江海昇药业股份有限公司 2024 年第二次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江海昇药业股份有限公司 2024 年第二次临时股东大会的 法律意见书 编号：TCYJS2024H0862 号 （二）本次会议采取现场投票与网络投票相结合的方式。 1 法律意见书 致：浙江海昇药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江海昇药业股份有限公司 （以下简称"海昇药业"或"公司"）的委托，指派本所律师参加贵公司 2024 年 第二次临时股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东大会 规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法规和其他 有关规范性文件的要求出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会表决程序及表决结果的合法 有效性发表意见，不对会议所审议的议案内容和 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-076 公司开立的现金管理产品专用结算账户不会存放非募集资金或者用作其他用途， 在现金管理产品到期且无下一步现金管理购买计划时，存放于该账户的现金管理本 金及累积的现金管理收益在返回公司募集资金专项账户后，公司将及时对该专用结 算账户进行注销。 特此公告。 浙江海昇药业股份有限公司 董事会 浙江海昇药业股份有限公司 关于开立募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开第 三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金进行现金管 理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提下，公司拟使 用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金管理，在上述额度 范围内资金可以循环滚动使用，并授权公 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-075 浙江海昇药业股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 6 月 3 日 2.会议召开地点：衢州市高新技术产业园区华阳路 36 号会议室 3.会议召开方式：现场投票和网络投票相结合方式 4.会议召集人：公司董事会 5.会议主持人：董事长叶山海先生 6.召开情况合法、合规、合章程性说明： 本次股东大会会议召集、召开、议案审议程序等方面符合有关法律、行政法 规、部门规章、规范性文件和公司章程的规定。 （二）会议出席情况 1.公司在任董事 6 人，出席 6 人； 2.公司在任监事 3 人，出席 3 人； 3.公司董事会秘书出席会议； 公司其他高级管理人员列席会议。 二、议案审议情况 （一）审议通过《关于使用部分闲置募集资金进行现金管理的议案》 1.议案内容： 具体内容详见公司于 2024 年 5 月 17 日 ...

一、权益分派方案 1、本公司 2023 年年度权益分派方案为： 证券代码：870656 证券简称：海昇药业 公告编号：2024-077 浙江海昇药业股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 浙江海昇药业股份有限公司 2023 年年度权益分派方案已获 2024 年 5 月 20 日召开的股东大会审议通过，本次实施分配方案距离股东大会审议通过的时间未 超过两个月。 现将权益分派事宜公告如下： 本次权益分派基准日未分配利润为 181,042,902.46 元，不存在纳入合并报表 范围的子公司。本次权益分派共计派发现金红利 40,000,000.00 元。 四、权益分派方法 1、本公司此次委托中国结算北京分公司代派的现金红利将于 2024 年 6 月 11 日 通过股东托管证券公司（或其他托管机构）直接划入其资金账户。 以公司现有总股本 80,000,000 股为基数，向全体股东每 10 股派 5.00 元人民 币现金。 2、扣税说明 （1）个人股东、投资基 ...